{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:56:39Z","timestamp":1783659399895,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> Pruritus is common in dialysis patients. Peripheral neuropathy is also prevalent in this patient population. However, the role of neuropathy in the genesis of uraemic itch has not been adequately studied to date. Therefore, we aimed to investigate the effects of gabapentin and pregabalin on uraemic pruritus along with neuropathic pain in patients receiving haemodialysis.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> This is a 14\u2003week long randomized, prospective, cross\u2010over trial. Haemodialysis patients with established neuropathy and\/or neuropathic pain were included. Fifty patients were randomly assigned to gabapentin 300\u2003mg after each haemodialysis session and pregabalin 75\u2003mg daily. After 6 weeks of treatment, cross\u2010over was performed and patients received the other drug for another 6 weeks. Short Form of McGill Pain Questionnaire and Visual Analogue Scale were used to evaluate pain and pruritus, respectively. At each week's visit, patients were interrogated in terms of adverse effects of study drugs. Baseline laboratory data and demographic characteristics were recorded from patient charts.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Forty (12 males, 28 females) out of 50 patients completed the study. Mean age was 58.2\u2003\u00b1\u200313.7. Overall, 29 out of 40 patients (72.5%) had pruritus symptoms at baseline evaluation. Fifteen patients (37.5%) were diabetic. Thirty\u2010one out of 40 patients (77.5%) had electromyography (EMG)\u2010proven peripheral neuropathy. Twenty three patients (57.5%) had both EMG\u2010proven neuropathy and pruritus. Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly. There was no difference between the study drugs in terms of efficacy against pain and pruritus.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2012.01655.x","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T07:39:20Z","timestamp":1345621160000},"page":"710-717","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study"],"prefix":"10.1111","volume":"17","author":[{"given":"YALCIN","family":"SOLAK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZEYNEP","family":"BIYIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUSEYIN","family":"ATALAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABDUZHAPPAR","family":"GAIPOV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FIGEN","family":"GUNEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SULEYMAN","family":"TURK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADRIAN","family":"COVIC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID","family":"GOLDSMITH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MEHMET","family":"KANBAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002197"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl461"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000251"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0806"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2008.00167.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1526-5900(03)00637-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.494"},{"issue":"4","key":"e_1_2_6_9_2","first-page":"244","article-title":"Central neurogenic pruritus: A literature review","volume":"97","author":"Canavero S","year":"1997","journal-title":"Acta Neurol. Belg."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-5-7"},{"issue":"1","key":"e_1_2_6_11_2","first-page":"86","article-title":"Gabapentin in the treatment of uremic itch: An index case and a pilot evaluation","volume":"18","author":"Manenti L","year":"2005","journal-title":"J. Nephrol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh496"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0987-7053(01)00257-X"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-6686.2010.00190.x"},{"key":"e_1_2_6_15_2","first-page":"202","volume-title":"Clinical Electromyography: Nerve Conduction Studies","author":"Oh SJ","year":"2003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8"},{"key":"e_1_2_6_17_2","first-page":"47","article-title":"McGill Melzack a\u011fr\u0131 soru formunun T\u00fcrk\u00e7e'ye uyarlanmas\u0131","volume":"15","author":"Ku\u011fuo\u011flu S","year":"2003","journal-title":"A\u011fr."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L038"},{"issue":"4","key":"e_1_2_6_19_2","first-page":"443","article-title":"[Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)]","volume":"38","author":"Russo GE","year":"1986","journal-title":"Minerva Urol. Nefrol."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027092"},{"issue":"2","key":"e_1_2_6_21_2","first-page":"161","article-title":"Uremic pruritus in chronic hemodialysis patients","volume":"21","author":"Narita I","year":"2008","journal-title":"J. Nephrol."},{"issue":"2","key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2340\/0001555572102105","article-title":"Cutaneous innervation in chronic renal failure patients. An immunohistochemical study","volume":"72","author":"Fantini F","year":"1992","journal-title":"Acta Derm. Venereol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B"},{"issue":"3","key":"e_1_2_6_24_2","first-page":"168","article-title":"The search for new off\u2010label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs","volume":"31","author":"Chouinard G","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04537.x"},{"issue":"2","key":"e_1_2_6_26_2","first-page":"1","article-title":"Pruritus: Control of itch in patients undergoing dialysis","volume":"15","author":"Mettang M","year":"2010","journal-title":"Skin Therapy Lett."},{"issue":"3","key":"e_1_2_6_27_2","first-page":"378","article-title":"Gabapentin: A promising drug for the treatment of uremic pruritus","volume":"18","author":"Naini AE","year":"2007","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220802595476"},{"issue":"2","key":"e_1_2_6_29_2","first-page":"71","article-title":"A2delta ligands gabapentin and pregabalin: Future implications in daily clinical practice","volume":"14","author":"Tzellos TG","year":"2010","journal-title":"Hippokratia"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00172-1"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.017"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.07.006"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000121500"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2012.01655.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2012.01655.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:48:21Z","timestamp":1697276901000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2012.01655.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1440-1797.2012.01655.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2012.01655.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,29]]},"assertion":[{"value":"2012-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}